

# **Certificate**

# **DISSOLUTION PERFORMANCE VERIFICATION STANDARD - PREDNISONE**

(10 mg nominal prednisone content per tablet)

USP Catalog No.: 1222818 USP Lot No.: F161Y0

Valid Use Date	14-NOV-2024
Storage/Handling	As per the label.
Uses	General Chapter <711> Dissolution, Performance Verification Test (PVT), Apparatus 1 and Apparatus 2, PF 48(2)

### Dissolution <711>

Medium: 499 g of degassed purified water maintained at 37° ± 0.5°

Medium degassing: Recommended degassing procedure: Heat a suitable amount of water, while stirring

gently to about 41-45°. Filter under vacuum through a 0.45- $\mu$ m-porosity filter into a suitable filtering flask equipped with a stirring device. Seal the flask and continue to apply vacuum while stirring for an additional five minutes. Measured vacuum should be

less than 100 mbar.

Note: Other validated degassing methods that reduce the total dissolved gas in the

media can also be used

Apparatus: Apparatus 1 (Basket) or Apparatus 2 (Paddle) at 50 RPM

Note: If equipment is dedicated for use with only one apparatus (basket or paddle),

then performance verification is only required for that apparatus

Time: 30 minutes

Standard Solution: A known concentration of USP Prednisone RS in Medium.

**Note**: An amount of alcohol not to exceed 5% of the total volume of the standard solution may be used to bring the prednisone reference standard into solution.

Sample solution: Laboratory can choose either Single-Stage Test or Optional Two-Stage Test scheme to

obtain Sample Solutions.

A filtered portion of the solution under test, suitably diluted, if necessary, with Medium

to obtain a concentration similar to that of the Standard solution. **Note 1**: The filtering method must not cause adsorptive loss of drug **Note 2**: Bias introduced by automated methods is to be avoided

Analysis: UV at maximum absorbance of about 242 nm

Copyright 2018 The United States Pharmacopeial Convention. All rights reserved.

**USP** Certificate

USP Template No.: CERT1-07

Template Effective Date: August 31, 2021 Page 1 of 6



### Dissolution <711>

Procedure: Determine the quantity of prednisone, C21H26O5, dissolved at 30 minutes in each vessel

expressed as percent of the labeled amount.

## **Single-Stage Test Instructions and Acceptance Criteria**

For each position in the assembly, test one USP Dissolution Performance Verification Standard –
Prednisone (DPVS – Prednisone) RS tablet, and record the percent dissolved at the sampling time point
specified. Transform the percent dissolved results to the natural log scale, determine the mean and
variance. For assemblies with 12 or 14 dissolution vessels, no further testing is required

- 2. For assemblies with fewer than 12 positions, repeat Step 1 with an additional set of tablets. Transform the percent dissolved results to the natural log scale, determine the mean and variance.
- Calculate the average of the two means and of the two variances obtained in Steps 1 and 2.
   Use the results from Step 1 alone for assemblies that have 12 or 14 positions.
- 4. Convert the results of Step 3 to a geometric mean (GM) and percent coefficient of variation (%CV). See Calculation Example for details.
- 5. Compare the results of Step 4 to the Single-Stage acceptance criteria in Table 1. The GM must not fall outside the limits, and the %CV must not be greater than the limit. If both meet the criteria, the assembly has passed the PVT

Table 1. Performance Verification Test Acceptance Criteria for Single-Stage Test

Apparatus	No. of vessels per run	Geometric Mean, % Prednisone Dissolved	%CV
1 (Basket)	6	81-92	4.6
	7	81-92	4.5
	8	82-92	4.4
	12	81-92	4.5
	14	81-92	4.5
2 (Paddle)	6	46-59	6.2
	7	46-59	6.1
	8	46-59	6.0
	12	46-59	6.1
	14	46-59	6.0

Page 2 of 6

Copyright 2018 The United States Pharmacopeial Convention. All rights reserved.

**USP** Certificate

USP Template No.: CERT1-07

Template Effective Date: August 31, 2021



## **Optional Two-Stage Test Instructions and Acceptance Criteria**

A laboratory may choose to implement the PVT as a Two-Stage test in case of assemblies with less than 12 positions. The Two-Stage test is a statistically valid means of allowing the possibility of stopping the test at the first stage using more stringent acceptance criteria. The following are step-by-step instructions for the two-stage test

- 1. For each position in the assembly, test one USP DPVS Prednisone RS tablet, and record the percent dissolved at the sampling time point specified. Transform the percent dissolved results to the natural log scale, determine the mean and variance
- 2. Convert the results of Step 1 to a GM and %CV and compare to the 1st Stage of Two Stages acceptance ranges in Table 2. The GM must not fall outside the limits, and the %CV must not be greater than the limit. For calculation of the GM and %CV, see Calculation Example for details
- 3. If results of Step 2 satisfy both acceptance criteria, the assembly has passed the PVT. Otherwise continue to Step 4. Prior to proceeding to Step 4, see Futility Factor section.
- 4. Repeat Step 1 with an additional set of tablets. Transform the percent dissolved results to the natural log scale determine the mean and variance for the data obtained at this step
- 5. Average the two means and two variances obtained in Steps 1 and 4
- 6. Convert the results of Step 5 to a geometric mean (GM) and percent coefficient of variation (%CV). For calculation of the GM and %CV, see Calculation Example for details
- 7. Compare the results of Step 6 to the 2nd Stage of Two Stages acceptance ranges in Table 2. The GM must not fall outside the limits, and the %CV must not be greater than the limit. If both meet the acceptance criteria, the assembly has passed the PVT

**Table 2. Performance Verification Test Acceptance Criteria for Two-Stage Test** 

Apparatus	No. of	First Stage of Two-Stage Test		Second Stage of Two-Stage Test	
	vessels per run	Geometric Mean, % Prednisone Dissolved	%CV	Geometric Mean, % Prednisone Dissolved	%CV
1 (Basket)	6	83-90	3.4	81-92	4.5
	7	83-90	3.4	81-92	4.4
	8	83-90	3.4	82-92	4.3
2 (Paddle)	6	48-57	4.6	46-59	6.1
	7	48-57	4.6	46-59	6.0
	8	48-57	4.6	46-59	5.9

Copyright 2018 The United States Pharmacopeial Convention. All rights reserved.

**USP** Certificate

USP Template No.: CERT1-07

Template Effective Date: August 31, 2021 Page 3 of 6



## **Futility Factor**

If optional Stage-Two test is chosen, there are circumstances when the %CV after the First Stage of Two-Stage test equals or exceeds the value in the Futility Factor table (without rounding). In such cases it is impossible to meet the %CV criterion after the Second Stage of the Two-Stage test. The lab can stop after the First Stage run. However, after any adjustments to equipment, test procedure, and so on, the PVT must be restarted with a new first run (Step 1 of the two-stage test instructions).

## Futility Factor, %CV at or above value given, second stage testing will not produce passing result

Apparatus	Number of Vessels		
	6	7	8
1	6.4	6.2	6.1
2	8.6	8.5	8.4

## <u>Calculation Example</u> (expressed as Microsoft Excel® worksheet functions):

**Run 1**:  $x_1$ ,  $x_2$ , ...,  $x_n$  in natural log scale: Ln  $x_1$ , Ln  $x_2$ , ..., Ln  $x_n$ 

**Run 2**:  $x_{n+1}$ ,  $x_{n+2}$ , ...,  $x_{2n}$  in natural log scale: Ln  $x_{n+1}$ , Ln  $x_{n+2}$ , ..., Ln  $x_{2n}$ 

## 1st Stage of Two-Stage for n=6, 7, 8 and Single-Stage for n=12, 14:

GM1 = exp(average (Ln  $x_1$ :Ln  $x_n$ ))

 $%CV1 = 100*sqrt(exp(var(Ln x_1:Ln x_n)) -1)$ 

#### Single-Stage or 2nd Stage of Two-Stage for n= 6, 7, 8:

GM = exp(average((average (Ln  $x_1$ :Ln  $x_n$ )), (average (Ln  $x_{n+1}$ :Ln  $x_2$ )))) = exp(average (Ln  $x_1$ :Ln  $x_2$ ))

%CV= 100\*sqrt(exp(average((var( $Ln x_1:Ln x_n$ )),(var( $Ln x_{n+1}:Ln x_{2n}$ )))) -1)

exp: exponential (e<sup>x</sup>) var: variance sqrt: square root \*: multiply 100: conversion factor to percentage

For more information and guidelines about how to complete the performance verification test refer to the following website:

https://www.usp.org/small-molecules/pvt

Copyright 2018 The United States Pharmacopeial Convention. All rights reserved.

**USP** Certificate

USP Template No.: CERT1-07

Template Effective Date: August 31, 2021

Page 4 of 6



## **LABEL TEXT**



## REFERENCE STANDARD

## **DISSOLUTION PERFORMANCE VERIFICATION STANDARD -**PREDNISONE 30 Tablets

Not for use as a drug. tests.

use with specified USP compendial test SDS prior to use at www.usp.org/sds.

See

The nominal weight of prednisone in each tablet is 10 mg. At the time of use, open the aluminum sachet, remove the blister card, and push the tablets through the foil backing of the blister card. Use only whole tablets. Store at controlled room temperature. Keep unused or unopened blister strips in the secondary package.

Danger! Causes eye irritation. Suspected of damaging fertility or the unborn child. Causes damage to organs (endocrine system) through prolonged or repeated exposure.

Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Do not breathe dust/fume/gas/mist/vapors/spray. Wash thoroughly after handling. Wear protective gloves/protective clothing/eye protection/face protection. If in eyes: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists: Get medical advice/attention. If exposed or concerned: Get medical advice/attention. Store locked up. Dispose of contents/container in accordance with local/regional/national/international regulations.

See certificate for any additional information.

USP, 12601 Twinbrook Pkwy, Rockville, MD, +1-301-881-0666 Cat. No. 1222818 Material mfd. in Spain

LOT: F161Y0



Danielle A. Vattimo

**Quality Assurance** 

## **Certificate Version History**

Version Number	Date	Reasons for Change
00 (Current)	17-JAN-2023	First issue

Copyright 2018 The United States Pharmacopeial Convention. All rights reserved.

**USP** Certificate

USP Template No.: CERT1-07

Template Effective Date: August 31, 2021



## **Assigned Value**

Please refer to the USP Reference Standard label and/or USP Certificate for the assigned value of the specific lot. Ifan assigned value is not included on the label or Certificate, the lot was developed for qualitative USP compendial use and an assigned value will not be provided.

#### Valid Use Date

It is the responsibility of the user to ascertain that a particular lot of a USP Reference Standard has official status either as a "Current Lot" or as a "Previous Lot" within the assigned valid use date. The online USP Reference Standards Catalog and the online USP Store at <a href="https://www.usp.org">www.usp.org</a> are updated daily. USP recommends referring to one of these sources prior to using a USP RS to make sure the lot is valid for use.

#### **Storage**

Storage conditions are lot—specific and may change from one lot to another. The storage condition for an unopened USP Reference Standard is provided on the container label only, not on the Safety Data Sheet. If no specific directions or limitations are on the label, conditions of storage include storage at room temperature and protection from moisture, light, freezing, and excessive heat. See General Chapter <659> in the USP-NF Online for storage and handling definitions.

### Instructions for Use

Follow the instructions provided on this Certificate, on the label of the USP Reference Standard, and in the associated USP documentary standard(s). Please refer to General Chapter <11> for additional information.

## **Non-USP Compendial Use**

USP Reference Standards are intended only for use in analytical or laboratory applications generally as specified in USP compendia. They are not for use in humans or animals as drugs or medical devices. It may be possible to use a USP RS outside of its associated USP compendial applications; however, it is the responsibility of the user to determine the suitability of the USP RS for a non-USP use.

### **LEGAL NOTICE**

USP WARRANTS GOOD TITLE TO USP REFERENCE STANDARDS ON DISPATCH FROM USP. THE FOREGOING WARRANTY IS IN LIEU OF ANY OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY THAT THE PRODUCTS, INCLUDING THIS CERTIFICATE, ARE OF MERCHANTABLE QUALITY. USP'S LIABILITY ARISING OUT OF OR RELATING TO THE SUPPLY OF USP REFERENCE STANDARDS AND THIS CERTIFICATE SHALL IN NO EVENT INCLUDE LOSS OF PROFITS, COST OF PROCURING SUBSTITUTE GOODS OR SERVICES, OR ANY INCIDENTAL, INDIRECT, OR CONSEQUENTIAL DAMAGES OF ANY KIND, EVEN IF USP IS AWARE OF THE POSSIBILITY OF SUCH DAMAGES. WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, USP DOES NOT WARRANT THAT THE USE OR RESALE OF USP REFERENCE STANDARDS, INCLUDING THEIR USE TO PERFORM TESTS AND ASSAYS PUBLISHED BY USP, WILL NOT INFRINGE UNITED STATES OR ANY OTHER PATENTS.

USP Reference Standards are not intended for use as drugs, dietary supplements, or as medical devices.

This certificate may not be reproduced without the express written permission of USP.